Twist Bioscience Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Twist Bioscience şirketinin toplam hissedar öz sermayesi $445.7M ve toplam borcu $15.0M olup, bu da borç-öz sermaye oranını 3.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $672.4M ve $226.7M dir.
Anahtar bilgiler
3.37%
Borç/özkaynak oranı
US$15.00m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$166.84m |
| Eşitlik | US$445.74m |
| Toplam yükümlülükler | US$226.70m |
| Toplam varlıklar | US$672.44m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Sep 03
TWST: AI Drug Discovery Hype Will Likely Outrun 2026 Execution Reality
Analysts have raised the fair value estimate for Twist Bioscience from $38.04 to $57.50, citing a series of higher Street price targets clustered around $95 to $120. These targets are linked to updated models following Q3 results and growing expectations for revenue contributions from AI-enabled drug discovery.Seeking Alpha • Aug 20
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Summary Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist. TWST stock's upside hinges on future AI-driven healthcare markets, but near-term volatility and speculative sentiment dominate the investment case. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 13
TWST: AI Order Momentum Will Test Sustainability After Equity Raise
Analysts have lifted the Twist Bioscience fair value estimate from $92.50 to $105.30, citing refreshed models that reflect updated revenue expectations, AI-enabled drug discovery order trends, and revised sector assumptions across recent research. Analyst Commentary Recent Street research around Twist Bioscience shows a cluster of higher fair value targets and mostly positive views on execution, with one more cautious voice highlighting valuation risks after a strong share price run.Analiz Makalesi • Aug 06
Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104
Shareholders will be ecstatic, with their stake up 35% over the past week following Twist Bioscience Corporation 's...Anlatı Güncellemesi • Jul 30
TWST: AI Drug Discovery Hopes Face Sector And Execution Headwinds
The updated analyst price target for Twist Bioscience moves from $71.10 to $92.50 as analysts refresh models around higher assumed revenue growth, a lower discount rate, and a higher future P/E multiple, partly offset by more conservative profit margin expectations. Analyst Commentary Recent Street research on Twist Bioscience points to an active debate on valuation and execution as the stock responds to shifting expectations around growth, margins, and the broader life science tools sector.
Anlatı Güncellemesi • Jul 16
TWST: AI Drug Discovery Demand Will Shape Multi Year Upside Potential
Analysts have raised the fair value estimate for Twist Bioscience to $120 from $95, reflecting updated models that incorporate slightly higher revenue growth assumptions, adjusted profit margin expectations, and a higher future P/E, in line with a series of recent price target increases across the Street. Analyst Commentary Bullish analysts covering Twist Bioscience have been revisiting their models, with a series of higher price targets and positive views on the company’s execution in life science tools and synthetic biology.Anlatı Güncellemesi • Jul 02
TWST: AI Drug Discovery Exposure And Tools Recovery Will Shape Multi Year Outlook
The analyst fair value estimate for Twist Bioscience has been revised from $58.00 to $95.00. This change reflects updated sector views and recent price target increases across the Street.Analiz Makalesi • Jun 18
Twist Bioscience (TWST) Stock Looks 42.9% Overvalued After Bullish Analyst Calls
Recent bullish coverage from firms such as Canaccord Genuity, highlighting Twist Bioscience (TWST) silicon-based lab-on-a-chip platform and AI-enabled drug discovery efforts, has pushed Twist Bioscience stock firmly into focus for many investors. See our latest analysis for Twist Bioscience. That bullish research comes after a sharp move in the Twist Bioscience share price. The stock closed at US$82.87, with a 30 day share price return of 66.44% and a 1 year total shareholder return of...Anlatı Güncellemesi • Jun 18
TWST: AI Drug Discovery Hopes Will Be Tested By Sector Headwinds
The analyst fair value estimate for Twist Bioscience has been lifted from $64.38 to $71.10. Analysts point to a higher assumed revenue growth rate, a richer future P/E and sector research that highlights the company’s growing role in next generation drug discovery and development as key factors in the new price target.Anlatı Güncellemesi • Jun 04
TWST: AI Drug Discovery Hopes Will Outrun Earnings Execution Risk
The analyst price target for Twist Bioscience has been revised higher to $64.38 from $63.33. Analysts point to updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E as key drivers of the change.Anlatı Güncellemesi • May 20
TWST: Silicon DNA Platform And Profitability Shift Will Drive Bullish Repricing
Analysts have raised their average price target for Twist Bioscience to about $63.33 from $55.00, citing updated assumptions around profitability, modest tweaks to discount rates and growth, and a lower future P/E multiple as key inputs in their models. Analyst Commentary Recent research on Twist Bioscience centers on how updated profitability assumptions and valuation frameworks translate into higher price targets, with several analysts revising their models over a short period.Anlatı Güncellemesi • Apr 29
TWST: Silicon DNA Platform And Expanded Partnerships Will Shape Balanced Risk Reward Profile
Twist Bioscience's analyst fair value estimate has been reset from $35.63 to $55.00. Analysts point to a series of recent price target increases from firms such as Barclays, Evercore ISI, Guggenheim and Baird as support for the higher range.Anlatı Güncellemesi • Apr 15
TWST: Bispecific Platform Deal And Tools Recovery Will Shape Multi Year Outlook
Twist Bioscience's updated analyst price target remains at $58.00. Recent Street research cites revised assumptions around revenue growth, profitability, and a lower future P/E as key drivers behind the refreshed narrative.Anlatı Güncellemesi • Mar 30
TWST: Sector Recovery Hopes Will Likely Outpace 2026 Execution Reality
Analysts have lifted the implied fair value estimate for Twist Bioscience by about $5 to roughly $38 per share, citing refreshed models that incorporate updated 2026 frameworks, recovering end markets and multiple avenues for growth reflected in recent price target increases from firms across the diagnostic tools peer group. Analyst Commentary Recent Street research on Twist Bioscience has centered on refreshed 2026 frameworks, sector rotation within diagnostic tools and how quickly end markets are recovering.Anlatı Güncellemesi • Mar 16
TWST: 2026 Tools Recovery And Bispecific Deal Will Support Multi Year Upside
Analysts have raised their average price targets on Twist Bioscience by double digit dollar amounts. Firms such as Baird, Evercore ISI, Barclays, Guggenheim and TD Cowen have cited recovering end markets, improving sentiment into 2026 and multiple avenues for upside to previously derisked growth assumptions.Anlatı Güncellemesi • Mar 02
TWST: 2026 Tools Recovery Framework Will Drive Multi Year Platform Upside
Analysts have lifted their price targets on Twist Bioscience by $8 to $17 per share in recent research, tying the changes to improving tools sector sentiment, recovering end markets into 2026, and what they view as multiple avenues for upside within a clearer multi year growth framework. Analyst Commentary Bullish analysts are clustering around a more constructive view on Twist Bioscience, pointing to a clearer multi year growth framework and a tools sector that they see as recovering into 2026.Anlatı Güncellemesi • Feb 16
TWST: Multi Year Tools Framework Will Drive DNA Synthesis Platform Upside
Analysts have raised their price targets for Twist Bioscience, supporting a fair value move from $42.00 to $58.00. They cite a clearer multi year growth framework, recovering end markets, and a tools focused setup into 2026.Anlatı Güncellemesi • Feb 02
TWST: Sector Recovery Optimism Will Likely Outrun Synthetic Biology Market Realities
Analysts have lifted their price targets on Twist Bioscience by up to about $10, citing improving sentiment into 2026, recovering end markets, and what they see as multiple potential avenues for growth in the tools and synthetic biology businesses, despite some remaining questions on market size. Analyst Commentary Recent research commentary has generally leaned constructive on Twist Bioscience, with several firms lifting their price targets and pointing to tools and synthetic biology as potential growth drivers into 2026.Anlatı Güncellemesi • Jan 19
TWST: Sector Recovery Hopes Will Likely Overstate Synthetic Biology Upside
Analysts have raised their fair value estimate for Twist Bioscience to $33 from $25, citing higher assumed revenue growth, improved profit margins, and future P/E multiples supported by recent price target increases and commentary regarding sector recovery, multi-year growth frameworks, and share gains in DNA synthesis. Analyst Commentary Recent Street research on Twist Bioscience reflects a mix of optimism and restraint, with several firms revisiting their price targets and highlighting both potential upside drivers and key execution questions.Analiz Makalesi • Jan 14
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 30%
The Twist Bioscience Corporation ( NASDAQ:TWST ) share price has done very well over the last month, posting an...Anlatı Güncellemesi • Jan 05
TWST: Commercial Execution Will Drive DNA Synthesis Platform Toward Profitable Scale
Analysts have trimmed their price target on Twist Bioscience from $50 to $42 per share. This reflects a slightly higher discount rate and more tempered revenue growth expectations, even as they acknowledge the company’s differentiated DNA synthesis platform, cost leadership, and continued market share gains.Anlatı Güncellemesi • Dec 15
TWST: Silicon DNA Platform And Aggressive Commercial Push Will Drive Share Gains
Analysts have modestly trimmed their price target on Twist Bioscience by a few dollars per share to better reflect lingering questions around the size and timing of synthetic biology opportunities, even as they highlight the company’s differentiated, cost advantaged DNA synthesis platform and ongoing share gains as key drivers of long term upside. Analyst Commentary Bullish analysts emphasize that Twist’s differentiated, technology driven DNA synthesis platform, built on proprietary silicon chip technology, underpins a durable competitive moat that can support premium growth and multiple expansion over time.Anlatı Güncellemesi • Dec 01
TWST: Silicon Chip DNA Platform Will Drive Continued Market Share Gains
Analysts have slightly raised their fair value estimate for Twist Bioscience to $35.63 from $35.57 per share. They cite ongoing market share gains and commercial momentum, even as questions remain about future growth opportunities.Anlatı Güncellemesi • Nov 17
TWST: Silicon Chip Technology Will Drive Future Market Share Gains
Analysts have lowered their price target for Twist Bioscience from $39.43 to $35.57, citing stable yet competitive end markets, slightly reduced growth expectations, and a longer path to profitability. Analyst Commentary Recent research from the Street highlights a mix of optimism and caution in outlooks for Twist Bioscience.Anlatı Güncellemesi • Nov 01
TWST: Share Valuations Will Stabilize As End Markets Remain Strong
Analysts have lowered their price target for Twist Bioscience to $40 from $45, citing stable end markets and improved sentiment as share valuations adjust. Analyst Commentary Bullish Takeaways Bullish analysts highlight that end markets remain stable, which supports reliable performance in the near term.Anlatı Güncellemesi • Oct 18
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have revised Twist Bioscience’s price target downward from $40.00 to $39.43, citing stable end markets and expectations of improving sentiment as the primary rationale for the modest adjustment. Analyst Commentary Recent analyst updates on Twist Bioscience reflect a nuanced perspective on the company’s outlook, highlighting both potential opportunities and ongoing challenges that could influence near-term valuation and long-term growth prospects.Analiz Makalesi • Oct 09
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%
Those holding Twist Bioscience Corporation ( NASDAQ:TWST ) shares would be relieved that the share price has rebounded...Anlatı Güncellemesi • Oct 04
SynBio And NGS Demand Will Broaden Global Market Reach
Analysts have lowered their price target for Twist Bioscience from $42.14 to $40.00. They cite stable end markets and a cautiously optimistic outlook based on current valuations and improved profit margin expectations.Anlatı Güncellemesi • Sep 19
SynBio And NGS Demand Will Broaden Global Market Reach
Twist Bioscience’s consensus price target increased to $42.14, as a higher future P/E suggests elevated growth expectations despite a decline in net profit margin. What's in the News Collaborated with Synthetic Design Lab, utilizing proprietary tools to support SDL's research activities.Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: TWST 'nin kısa vadeli varlıkları ( $321.3M ) kısa vadeli yükümlülüklerini ( $120.3M ) aşıyor.
Uzun Vadeli Yükümlülükler: TWST şirketinin kısa vadeli varlıkları ( $321.3M ) uzun vadeli yükümlülüklerini ( $106.4M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: TWST şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: TWST şirketinin borç/öz sermaye oranı son 5 yılda 0.4% seviyesinden 3.4% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: TWST şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.
Tahmini Nakit Akışı: TWST tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.
Sağlıklı şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/13 03:32 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Twist Bioscience Corporation 17 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |